research use only
Cat.No.S8054
| Related Targets | EGFR VEGFR PDGFR FGFR c-Met Src MEK CSF-1R FLT3 HER2 |
|---|---|
| Other ALK Inhibitors | TAE684 (NVP-TAE684) GSK1838705A Repotrectinib (TPX-0005) AZD3463 Ensartinib dihydrochloride AP26113-analog (ALK-IN-1) NVL-655 (Neladalkib) Envonalkib Belizatinib (TSR-011) HG-14-10-04 |
| Molecular Weight | 580.74 | Formula | C29H40N8O3S |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 1097917-15-1 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | CC(C)S(=O)(=O)C1=CC=CC=C1NC2=NC(=NC=N2)NC3=C(C=C(C=C3)N4CCC(CC4)N5CCN(CC5)C)OC | ||
|
In vitro |
DMSO
: 14 mg/mL
(24.1 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Features |
ALK-selective inhibitor that has been tested in Phase I clinical trials for treatment of solid tumors and B-cell lymphoma.
|
|---|---|
| Targets/IC50/Ki |
ALK
3.5 nM
|
| In vitro |
ASP3026 shows more selective ALK inhibition in a Tyr-kinase panel than PF02341066. This compound inhibits the growth of NCI-H2228, a human NSCLC tumour cell line endogenously expressing EML4-ALK variant 3, with an IC50 value of 64.8 nM.
|
| In vivo |
ASP3026, administered to mice bearing subcutaneous NCI-H2228 tumour xenografts as twice daily oral dosing for 14 days, induces dose dependent anti-tumour effects starting at 1 mg/kg with strong regression at 10, 30 and 100 mg/kg.
|
References |
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT01401504 | Completed | Solid Tumor |
Astellas Pharma Inc |
May 2011 | Phase 1 |
| NCT01284192 | Completed | Advanced Malignancies|Positive for Anaplastic Lymphoma Kinase|Positive for Proto-Oncogene Tyrosine-Protein Kinase ROS|Solid Tumor|B-Cell Lymphoma |
Astellas Pharma Inc |
December 2010 | Phase 1 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.